[DOI] [PubMed] [Google Scholar] 100.Jia SJ, Jiang DJ, Hu CP, Zhang XH, Deng HW, Li YJ
Several active research areas include: Metabolic dysfunction-associated steatotic liver disease (MASLD) : Multiple trials are evaluating semaglutide's effects on liver fat content and biomarkers, with preliminary data suggesting potential benefits in reducing hepatic steatosis and improving liver enzyme profiles Chronic kidney disease : Studies examining renal outcomes in patients with type 2 diabetes and established kidney disease, building on secondary analyses from SUSTAIN 6 showing reduced progression of diabetic nephropathy Obstructive sleep apnea : Ongoing trials investigating whether weight loss achieved with semaglutide improves sleep apnea severity and related cardiovascular outcomes Addiction and substance use disorders : Early-phase research exploring GLP-1 receptor agonists' potential effects on reward pathways and addictive behaviors, though this remains highly preliminary Alzheimer's disease and cognitive function : Preclinical evidence suggesting neuroprotective properties has prompted clinical trials examining cognitive outcomes in at-risk populations Researchers are also investigating combination therapies , such as cagrilintide plus semaglutide (CagriSema), which is currently under development
This is standard medical advice for gastric distress from Johns Hopkins Medicine
Ok, my fault, I have applied too much, too soon, I thought
Therefore, IL-1 inhibition can be seen as a potential therapeutic target in vitiligo
The pelleted l-EVs were re-suspended in 1 ml of filtered PBS and centrifuged again at 10,000 g for 30 min at 4 C using MX-307 centrifuge and AR015-24 rotor (TOMY, k-factor: 643)
